BrightSpring Health Services combined with PharMerica Corporation in early 2019 and is one of the largest health services companies in the U.S., as a leading pharmacy solutions company and home and community based health services provider. The company serves the largest populations in U.S. healthcare and provides clinical, pharmacy, and non-clinical services to complex Seniors, Specialty, and Behavioral individuals. Through its overlapping pharmacy and provider services that customers receive, the company is continuing to build upon its unique platform of high quality and integrated offerings, which provide significant value to the healthcare system, patients, and families. PharMerica is a leading U.S. pharmacy services provider to the long-term care, hospital, behavioral, specialty home infusion, and oncology pharmacy markets. The business operates approximately 130 long-term care and specialty pharmacies in 45 states. PharMerica is a customer service and patient focused organization serving skilled nursing facilities, senior living communities, behavioral group homes and individuals, mental health pharmacies and individuals, hospitals, other individuals receiving in-home care, and patients with cancer. BrightSpring Health Services is one of the largest providers of diversified home and community-based health services to complex populations. The company provides both nonclinical habilitative services and clinical rehabilitative services for people of all ages and skill levels. Its primary businesses include: home health care (including personal care, home health, and hospice); neuro rehabilitation therapies; behavioral health (including autism services); telecare ancillary technologies and services; and job placement and vocational training. BrightSpring is focused on providing quality and lower-cost outcomes to high-need populations through best-in-class services and investments in people, processes, and technology innovation.

Led the $2 billion Rehab Division at Kindred - the largest rehabilitation company in the United States by sites of service, with over 25,000 employees / caregivers in over 2,300 locations - consisting of 7 business segments, including freestanding IRFs (inpatient rehabilitation facilities ("rehab hospitals")) subsequent to the Centerre acquisition (January, 2015), acute rehab units in hospitals, outpatient rehab clinics, contract therapy in med/surg units of hospitals, long-term hospitals, skilled nursing facilities, and assisted / independent living facilities, 3rd party Part B therapy billing, and therapist staffing. The second largest freestanding IRF company (with a unique joint venture model consisting of partnerships with leading hospital systems) and largest IRF (including ARUs) company in the U.S, by sites of service and managed revenue. Drove leadership and growth through service, clinical, systems, sales, and people focused strategic initiatives, organic new facility developments, and differentiated business / corporate development partnerships. Executive Vice Presdient of Kindred Healthcare and Member of the Executive Committee of Kindred (NYSE: KND; over 100,000 employees operating in 46 states).

Led the Care Management division (including the Home Health & Hospice business, Home Based Primary Care, and integrated care management platforms and business models) with its 10,000 employees and healthcare professionals in 170 sites across the country. Completed and integrated numerous acquisitions, including Gentiva, and oversaw dramatic growth in the division. Reported to the President and COO and member of the Executive Committee of Kindred (NYSE: KND; 70,000 employees operating in 46 states).

Led global marketing, strategy and commercial development for Mylan Specialty and co-led billion dollar division in the Office of the President. Business unit sold all of Mylan’s branded products across consumer, office based physician, hospital, pharmacy, and payor channels in the allergy, respiratory, anesthesia, pain, and CNS therapy areas today. Led function (managing five brands, including EpiPen) consisting of strategy, business development, product planning, brand management, DTC (direct-to-consumer), digital, market expansion, professional affairs, public relations, advocacy, market research, managed markets, marketing operations, and sales effectiveness activities. Co-led organization decision making.

Led Marketing and Strategy (and various Sales initiatives) for Mylan’s North American platform ($3 billion business supplying 1 in 10 U.S. prescriptions) covering branded, branded generic, and generic products across four businesses, multiple channels (retail and specialty pharmacy, office based physicians, hospital, and payers), multiple technologies (oral solid, liquid capsule, transdermal, injectable, and inhalable), and 20 therapeutic categories. Ran strategy processes and ongoing strategic evaluations, including preparing for and defining biogeneric initiatives. Strategies and tactics included launching a new global master brand, launching numerous milestone products, and growing share of existing products.

Led commercial activities for the Continuous Glucose Monitoring (“CGM”) and Connectivity business (six product lines) at the world’s leading medical device company (and at the $1.3 billion division). Managed both upstream Product Planning (new product definition and developments) and downstream Product Marketing (market research, brand management (STP, core message platform, creative execution), market development, direct-to-consumer, product/customer education, competition, pricing, forecasting, sales integration, training and support) teams to grow existing products and launch new products. CGM coordination over R&D, Manufacturing, Quality, Clinical, Regulatory, Customer Service, Education, and Sales. Lean Sigma and QFD (Quality Function Deployment) training and Green Belts.

Created, prioritized and executed on strategies and growth initiatives in driving business development activities for multiple divisions ($1.5 billion) of the company. Performed diligence on and executed supply, joint development, license, distribution, and commercialization agreements, equity investments, new company formations, acquisitions, and (EU) divestitures in both medical devices and drug/device combination therapies. Venture Manager for partnered projects encompassing novel therapies. Core Team for development of new drug/device therapy. Led portfolio prioritization process and Research, Engineering, Clinical, and Manufacturing teams in product, market and financial assessments to execute milestone based business plans. Co-led the overall Medtronic Strategic Plan. Patient Access Acceleration ("PAA") training and neuroscience courses.

One of ten professionals investing an $800 million second private equity fund ($1.2 billion assets under management at the time) focused on leveraged acquisitions of growth companies and growth equity investments. Led cross-functional deal teams in executing transactions. Conducted business due diligence, structured investments and drafted proposals, developed detailed financial analyses and operating scenarios, negotiated deal documents, and coordinated debt financings and legal and accounting reviews. Evaluated markets and company strengths and weaknesses in due diligence, conducted detailed product, marketing, R&D, customer, supply chain, and facility reviews, assessed value propositions and management. Supported and developed portfolio company strategy and operations, regularly met with senior operating executives, developed financial reporting packages, drafted quarterly reports and annual reunderwriting reviews, wrote final investment memoranda and maintained intermediary relationships. Examined opportunities across a range of sectors including consumer products, business and financial services, IT, healthcare, industrial, and education.

Worked closely with firm’s four founding Partners (as first hire after formation) since inception of inaugural $350 million private equity fund. Involvement in all aspects of leveraged buyout and equity investment activities across a wide range of industries. Portfolio company interim CFO and Board Member. Led portfolio company budgets and strategies.

Financial Analyst, Investment Banking Division, Mergers & Acquisitions: Financial Institutions Group.Analyzed and executed mergers, acquisitions and divestitures for major financial institutions. Responsibilities included detailed valuation, analysis of financial impact and evaluation of strategic alternatives for financial institutions. Closed multiple sellside acquisitions that were the largest ever at the time. Provided M&A analysis for confidential Morgan Stanley strategic initiatives.Financial Analyst, Investment Banking Division, Real Estate Group. Evaluated principal investments for $1.5 billion real estate merchant banking fund. Performed M&A advisory, refinancings and equity offerings for REITs.